Put companies on watchlist
MeVis Medical Solutions AG
ISIN: DE000A0LBFE4
WKN: A0LBFE
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MeVis Medical Solutions AG · ISIN: DE000A0LBFE4 · EQS - adhoc news (10 News)
Country: Germany · Primary market: Germany · EQS NID: 1981763
04 September 2024 05:39PM

Adjusting forecast for the current fiscal year


EQS-Ad-hoc: MeVis Medical Solutions AG / Key word(s): Change in Forecast
MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year

04-Sep-2024 / 17:39 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Bremen, September 4, 2024 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, is adjusting its annual forecast for the current fiscal year based on the preliminary business figures for the first eleven months.

  • For fiscal year 2023/2024 (October 1, 2023 to September 30, 2024), sales are now expected to remain stable at between € 17.0 million and € 17.5 million (previous forecast for fiscal year 2023/2024: slight increase in sales from € 18.0 million to € 18.5 million).
  • EBIT (earnings before interest and taxes) is now expected to fall to between € 3.0 million and € 3.5 million in fiscal year 2023/2024 (October 1, 2023 to September 30, 2024) (previous forecast for fiscal year 2023/2024: stability in the range of € 4.5 million to € 5.0 million).

The reasons for the decline in sales are an unexpected cautiousness in purchasing behavior due to global economic challenges. In addition, the result will be strongly impacted by the development of the US dollar/euro exchange rate since the beginning of the fiscal year.

 

************************************************************************

 

Contact:
Kirchhoff, Marcus / CEO


End of Inside Information

04-Sep-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1981763

 
End of Announcement EQS News Service

1981763  04-Sep-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1981763&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - MeVis Medical Solutions AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.